[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345950-105":59,"doc-detail-345950-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-a-structurally-distinct-topbp1-inhibitor-that-enhances-parp-blockade-and-reverses-osimertinib-resistance-research-study","Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance - Research study","","Therapeutic resistance in cancer arises from compensatory signaling and stress response pathways that sustain tumor survival. TopBP1, a scaffold with nine BRCT domains, integrates replication stress signaling with oncogenic networks and is frequently overexpressed in aggressive cancers. Docking-guided screening and structure-activity optimization yielded CS18, a selective BRCT7/8 inhibitor that disrupts oncogenic TopBP1 complexes, suppresses MYC programs, restores E2F1 apoptosis, and triggers mitotic catastrophe. CS18 shows broad anticancer activity, synergizes with PARP inhibitors, and enhances osimertinib sensitivity, including in patient-derived xenografts and in vivo resistant models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-structurally-distinct-topbp1-inhibitor-that-enhances-parp-blockade-and-reverses-osimertinib-resistance-research-study/345950/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-structurally-distinct-topbp1-inhibitor-that-enhances-parp-blockade-and-reverses-osimertinib-resistance-research-study/345950.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is therapeutic resistance a major challenge in cancer treatment?","Question",{"text":112,"@type":113},"Resistance emerges as compensatory and convergent oncogenic signaling pathways activate and stress response pathways become increasingly relied upon, allowing relapse despite initial success.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is TopBP1 and why is it considered a promising target?",{"text":117,"@type":113},"TopBP1 is a multifunctional scaffold with nine BRCT domains that connects replication stress signaling to DNA replication, ATR activation, repair, mitosis, and transcriptional regulation, and it is often overexpressed in aggressive cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"How does CS18 affect cancer cells and therapy resistance?",{"text":121,"@type":113},"CS18 disrupts oncogenic TopBP1 complexes via BRCT7/8 inhibition, suppresses MYC transcriptional programs, restores E2F1-mediated apoptosis, induces mitotic catastrophe, and enhances sensitivity to PARP inhibitors and osimertinib while reversing osimertinib resistance in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345950,1790198007,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","CANCER  \nDevelopment of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance  \nFang-Tsyr Lin1,2*, Shwu-Jiuan Lin3,4, Kang Liu1,2, Yang Xiao1,2, Lidija A. Wilhelms Garan1,5, Helena Folly-Kossi1,2, Weei-Chin Lin1,2,5,6*  \nTherapeutic resistance remains a major challenge in cancer treatment, driven by compensatory signaling and stress response pathways that sustain tumor survival. Topoisomerase IIβ-binding protein 1 (TopBP1), a multifunctional scaffold protein with nine BRCT domains, integrates replication stress signaling with oncogenic networks and is frequently overexpressed in aggressive cancers. Its BRCT7/8 domains mediate critical interactions with E2F1, mutant p53, MIZ1, PLK1, and CIP2A, making TopBP1-BRCT7/8 an attractive therapeutic target. Using docking-guided screening and structure-activity relationship–driven optimization, we developed CS18 as a potent and selective BRCT7/8 inhibitor that disrupts oncogenic TopBP1 complexes without interfering with DNA replication. CS18 suppresses MYC transcriptional programs, restores E2F1-mediated apoptosis, and induces mitotic catastrophe. It exhibits broad-spectrum anticancer activity and synergizes with poly(ADP-ribose) polymerase (PARP) inhibitors in multiple cancer types and enhances osimertinib sensitivity in EGFR-mutated non–small cell lung cancer (NSCLC) cells. CS18 demonstrates efficacy in patient-derived breast cancer xenografts and overcomes osimertinib resistance in refractory NSCLC in vivo. These findings establish CS18 as a chemically distinct TopBP1 inhibitor with translational potential to overcome therapeutic resistance and advance precision oncology.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution noncommercial License 4.0 (cc BY-nc) .  \nINTRODUCTION  \nTherapeutic resistance represents a central barrier to durable cancer control. Although targeted therapies and precision medicine have transformed cancer treatment, most patients eventually relapse due to the activation of compensatory and convergent oncogenic signaling pathways and increased reliance on stress response pathways. These redundant networks allow cancer cells to bypass single-agent inhibition and promote survival and progression despite initial therapeutic success. Therefore, strategies that simultaneously target convergent signaling hubs or exploit pathway interdependencies are critical to achieve durable responses and overcome resistance.  \nTopoisomerase IIβ-binding protein 1 (TopBP1) has emerged as a critical hub linking replication stress signaling to multiple oncogenic pathways (1) . This multifunctional scaffold protein contains nine BRCT domains that coordinate DNA replication, ATR activation, DNA repair, mitosis, and transcriptional regulation (2) . TopBP1 promotes replication by binding Cdk2-phosphorylated Treslin and activates ATR under replication stress (3, 4) . TopBP1 overexpression is associated with a shorter survival in many types of cancer, such as breast cancer (5, 6), lung cancer, ovarian cancer, and leukemia (7) . TopBP1 overexpression drives tumor progression by suppressing E2F1-mediated apoptosis (8–10), enhancing mutant p53 (mutp53) gain of function (6), bypassing Cdk2 dependency (11), and impairing ATR/Chk1 signaling (12) . The C-terminal BRCT7/8 domains of TopBP1 mediate phosphorylation-dependent self-oligomerization  \n1Section of hematology/Oncology, department of Medicine, Baylor college of Medicine, houston, tX 77030, USA. 2dan L. duncan cancer center, Baylor college of Medicine, houston, tX 77030, USA. 3department of Pharmaceutical Sciences, School of Pharmacy, taipei Medical University, taipei 11031, taiwan. 4Phd Program in clinical drug development of herbal Medicine, college of Pharmacy, taipei Medical University, taipei 11031, taiwan. 5cancer and ce","cbCaidILY9dSgMNk","https://ap.wps.com/l/cbCaidILY9dSgMNk","pdf",8829054,"English","# Introduction\n## Therapeutic resistance and convergent signaling pathways\n## TopBP1 as a replication stress hub\n## Rationale for targeting BRCT7/8 domains","[{\"question\":\"Why is therapeutic resistance a major challenge in cancer treatment?\",\"answer\":\"Resistance emerges as compensatory and convergent oncogenic signaling pathways activate and stress response pathways become increasingly relied upon, allowing relapse despite initial success.\"},{\"question\":\"What is TopBP1 and why is it considered a promising target?\",\"answer\":\"TopBP1 is a multifunctional scaffold with nine BRCT domains that connects replication stress signaling to DNA replication, ATR activation, repair, mitosis, and transcriptional regulation, and it is often overexpressed in aggressive cancers.\"},{\"question\":\"How does CS18 affect cancer cells and therapy resistance?\",\"answer\":\"CS18 disrupts oncogenic TopBP1 complexes via BRCT7/8 inhibition, suppresses MYC transcriptional programs, restores E2F1-mediated apoptosis, induces mitotic catastrophe, and enhances sensitivity to PARP inhibitors and osimertinib while reversing osimertinib resistance in vivo.\"}]","Development of a structurally distinct TopBP1 inhibitor that enhances PARP blockade and reverses osimertinib resistance - Research study | PDF",1790059505,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d00b0cb173d2f0301fcaf5e3038772bc.webp",983,1250,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a87d89b56d40f48f99aedf223c080f8.webp",982,1249,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc6e45e94bf163ad52e2625056a4b3e2.webp",981,1248,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4a19654dee1d2c84dbd937b8082e334.webp",980,1247]